Literature DB >> 21717528

Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records.

Sengwee Toh1, Luis A García Rodríguez, Miguel A Hernán.   

Abstract

PURPOSE: A semi-automated high-dimensional propensity score (hd-PS) algorithm has been proposed to adjust for confounding in claims databases. The feasibility of using this algorithm in other types of healthcare databases is unknown.
METHODS: We estimated the comparative safety of traditional non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors regarding the risk of upper gastrointestinal bleeding (UGIB) in The Health Improvement Network, an electronic medical record (EMR) database in the UK. We compared the adjusted effect estimates when the confounders were identified using expert knowledge or the semi-automated hd-PS algorithm.
RESULTS: Compared with the 411,616 traditional NSAID initiators, the crude odds ratio (OR) of UGIB was 1.50 (95%CI: 0.98, 2.28) for the 43,569 selective COX-2 inhibitor initiators. The OR dropped to 0.81 (0.52, 1.27) upon adjustment for known risk factors for UGIB that are typically available in both claims and EMR databases. The OR remained similar when further adjusting for covariates--smoking, alcohol consumption, and body mass index-that are not typically recorded in claims databases (OR 0.81; 0.51, 1.26) or adding 500 empirically identified covariates using the hd-PS algorithm (OR 0.78; 0.49, 1.22). Adjusting for age and sex plus 500 empirically identified covariates produced an OR of 0.87 (0.56, 1.34).
CONCLUSIONS: The hd-PS algorithm can be implemented in pharmacoepidemiologic studies that use primary care EMR databases such as The Health Improvement Network. For the NSAID-UGIB association for which major confounders are well known, further adjustment for covariates selected by the algorithm had little impact on the effect estimate.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717528      PMCID: PMC3222935          DOI: 10.1002/pds.2152

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  26 in total

Review 1.  A review of uses of health care utilization databases for epidemiologic research on therapeutics.

Authors:  Sebastian Schneeweiss; Jerry Avorn
Journal:  J Clin Epidemiol       Date:  2005-04       Impact factor: 6.437

2.  Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

Authors:  Tobias Kurth; Alexander M Walker; Robert J Glynn; K Arnold Chan; J Michael Gaziano; Klaus Berger; James M Robins
Journal:  Am J Epidemiol       Date:  2005-12-21       Impact factor: 4.897

3.  Variable selection for propensity score models.

Authors:  M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer
Journal:  Am J Epidemiol       Date:  2006-04-19       Impact factor: 4.897

4.  Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.

Authors:  A Lanas; L A García-Rodríguez; M T Arroyo; F Gomollón; F Feu; A González-Pérez; E Zapata; G Bástida; L Rodrigo; S Santolaria; M Güell; C M de Argila; E Quintero; F Borda; J M Piqué
Journal:  Gut       Date:  2006-05-10       Impact factor: 23.059

5.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

Authors:  Peter C Austin; Paul Grootendorst; Geoffrey M Anderson
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

6.  Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population.

Authors:  Luis A García Rodríguez; Laura Barreales Tolosa
Journal:  Gastroenterology       Date:  2006-12-03       Impact factor: 22.682

Review 7.  Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages.

Authors:  Samy Suissa; Edeltraut Garbe
Journal:  Nat Clin Pract Rheumatol       Date:  2007-12

8.  Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.

Authors:  Miguel A Hernán; Alvaro Alonso; Roger Logan; Francine Grodstein; Karin B Michels; Walter C Willett; Joann E Manson; James M Robins
Journal:  Epidemiology       Date:  2008-11       Impact factor: 4.822

Review 9.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Bryan; A Fry-Smith; G Harris; R S Taylor
Journal:  Health Technol Assess       Date:  2008-04       Impact factor: 4.014

Review 10.  Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review.

Authors:  Alaa Rostom; Katherine Muir; Catherine Dubé; Emilie Jolicoeur; Michel Boucher; Janet Joyce; Peter Tugwell; George W Wells
Journal:  Clin Gastroenterol Hepatol       Date:  2007-06-06       Impact factor: 11.382

View more
  37 in total

1.  High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications.

Authors:  E Garbe; S Kloss; M Suling; I Pigeot; S Schneeweiss
Journal:  Eur J Clin Pharmacol       Date:  2012-07-05       Impact factor: 2.953

Review 2.  Design and analysis of post-marketing research.

Authors:  Xiao-Hua Andrew Zhou; Wei Yang
Journal:  Chin J Integr Med       Date:  2013-07-02       Impact factor: 1.978

3.  On the role of marginal confounder prevalence - implications for the high-dimensional propensity score algorithm.

Authors:  Tibor Schuster; Menglan Pang; Robert W Platt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-04-10       Impact factor: 2.890

4.  The ACCE method: an approach for obtaining quantitative or qualitative estimates of residual confounding that includes unmeasured confounding.

Authors:  Eric G Smith
Journal:  F1000Res       Date:  2014-08-11

5. 

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Jean-Marie Januel; Erik von Elm; Sinéad M Langan
Journal:  CMAJ       Date:  2019-02-25       Impact factor: 8.262

6.  Commentary: Balancing automated procedures for confounding control with background knowledge.

Authors:  Richard Wyss; Til Stürmer
Journal:  Epidemiology       Date:  2014-03       Impact factor: 4.822

7.  Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs.

Authors:  T Stürmer; R Wyss; R J Glynn; M A Brookhart
Journal:  J Intern Med       Date:  2014-02-13       Impact factor: 8.989

Review 8.  Propensity score methods to control for confounding in observational cohort studies: a statistical primer and application to endoscopy research.

Authors:  Jeff Y Yang; Michael Webster-Clark; Jennifer L Lund; Robert S Sandler; Evan S Dellon; Til Stürmer
Journal:  Gastrointest Endosc       Date:  2019-04-30       Impact factor: 9.427

9.  A comparison of confounding adjustment methods for assessment of asthma controller medication effectiveness.

Authors:  Lingling Li; William M Vollmer; Melissa G Butler; Pingsheng Wu; Elyse O Kharbanda; Ann Chen Wu
Journal:  Am J Epidemiol       Date:  2014-01-23       Impact factor: 4.897

10.  Risk of Preterm or Small-for-Gestational-Age Birth After Influenza Vaccination During Pregnancy: Caveats When Conducting Retrospective Observational Studies.

Authors:  Gabriela Vazquez-Benitez; Elyse O Kharbanda; Allison L Naleway; Heather Lipkind; Lakshmi Sukumaran; Natalie L McCarthy; Saad B Omer; Lei Qian; Stanley Xu; Michael L Jackson; Vinutha Vijayadev; Nicola P Klein; James D Nordin
Journal:  Am J Epidemiol       Date:  2016-07-22       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.